Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse (scientific article published on 19 October 2011)

Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy

Q34857454

A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy

Q34990151

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells

Q35007831

Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells

Q35076645

Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice

Q35127565

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo

Q35149006

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

Q35158133

The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein

Q35211232

HIV-1 infection and pathogenesis in a novel humanized mouse model

Q35750948

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

Q36225040

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Q36499290

Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year

Q36756422

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

Q36851755

Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{ga

Q37275103

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

Q37393518

HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model

Q38905274

Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection

Q39686599

Generation of HIV latency during thymopoiesis

Q44072849

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Q46738531

Development of a human adaptive immune system in cord blood cell-transplanted mice

Q47819239

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Q52007779

Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Q53592113

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Q53869061

Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy

Q81314113

An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002

Q81767493

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

Q24548940

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

Q24596282

Primitive hematopoietic cells resist HIV-1 infection via p21

Q24681819

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Q28253761

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

Q28267375

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

Q29615993

Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells

Q33603453

A block to human immunodeficiency virus type 1 assembly in murine cells

Q33802821

Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors

Q33957283

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir

Q34097573

Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice

Q34100221

Molecular Characterization, Reactivation, and Depletion of Latent HIV

Q34263657

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy

Q34588169

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

114-120

P577

publication date

2011-10-19

P1433

published in

Journal of Virology

Q1251128

P1476

title

Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse

P478

volume

Reverse relations

cites work (P2860)

Q36601933	A Simple Mouse Model for the Study of Human Immunodeficiency Virus
Q46813659	An advanced BLT-humanized mouse model for extended HIV-1 cure studies.
Q26767476	Animal Models for HIV Cure Research
Q37041160	Animal models to achieve an HIV cure
Q37545050	Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs
Q37195155	Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?
Q38078562	Cellular and molecular mechanisms involved in the establishment of HIV-1 latency
Q33577361	Current advances in humanized mouse models
Q34474320	Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis
Q38973362	Current views on HIV-1 latency, persistence, and cure.
Q47582951	Frequency of Human CD45+ Target Cells is a Key Determinant of Intravaginal HIV-1 Infection in Humanized Mice
Q39018737	HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice
Q49990061	HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART.
Q37505823	HIV-1 Latency and Eradication: Past, Present and Future
Q37676228	HIV-1 immunopathogenesis in humanized mouse models
Q37305858	HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model
Q50146682	Humanized Mice as Unique Tools for Human-Specific Studies
Q92177909	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells
Q39459609	Humanized Mouse Models for Human Immunodeficiency Virus Infection.
Q59350579	Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses
Q37614202	Humanized Mouse Models of Clinical Disease
Q37111994	Humanized mice for immune system investigation: progress, promise and challenges
Q28728527	Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1
Q40548525	Humanized mouse as an appropriate model for accelerated global HIV research and vaccine development: current trend
Q39315707	In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies
Q36515119	In vivo platforms for analysis of HIV persistence and eradication
Q38126447	Infectious diseases in humanized mice
Q34434339	Is the central nervous system a reservoir of HIV-1?
Q38657287	Modeling the evolution of SIV sooty mangabey progenitor virus towards HIV-2 using humanized mice
Q60044574	Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART
Q42040218	Neutralizing the HIV reservoir
Q27014786	New generation humanized mice for virus research: comparative aspects and future prospects
Q36731941	Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1
Q63246353	Recent Updates on Mouse Models for Human Immunodeficiency, Influenza, and Dengue Viral Infections
Q37254480	Recent advances in humanized mice: accelerating the development of an HIV vaccine
Q27013114	Recent developments in human immunodeficiency virus-1 latency research
Q47608472	Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate-Dependent Mechanisms in Humanized Mice In Vivo
Q91752345	SIV progenitor evolution toward HIV: A humanized mouse surrogate model for SIVsm adaptation toward HIV-2
Q90430180	SIVcpz cross-species transmission and viral evolution toward HIV-1 in a humanized mouse model
Q35641175	Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research
Q26849806	Studies of retroviral infection in humanized mice
Q35685210	Study of viral pathogenesis in humanized mice
Q92860944	Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
Q38246141	Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions
Q39545359	The Application of Humanized Mouse Models for the Study of Human Exclusive Viruses.
Q36202761	Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells
Q28077662	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
Q92734574	Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression